Publications by authors named "Cath Trigwell"

Claim this Profile
I
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.
Kevin Hudson, Urs J Hancox, Cath Trigwell, Robert McEwen, Urszula M Polanska

Mol Cancer Ther· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Urs Hancox, Sabina Cosulich, Lyndsey Hanson, Cath Trigwell, Carol Lenaghan

Mol Cancer Ther· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.
Sarit Schwartz, John Wongvipat, Cath B Trigwell, Urs Hancox, Brett S Carver

Cancer Cell· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
Bernard Barlaam, Judith Anderton, Peter Ballard, Robert H Bradbury, Laurent F A Hennequin, Cath Trigwell

ACS Med Chem Lett· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
D Mark Hickinson, Teresa Klinowska, Georgina Speake, John Vincent, Cath Trigwell

Clin Cancer Res· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Bernard Barlaam, David G Acton, Peter Ballard, Robert H Bradbury, Darren Cross, Cath B Trigwell

Bioorg Med Chem Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Bernard Barlaam, Peter Ballard, Robert H Bradbury, Richard Ducray, Hervé Germain, Cath B Trigwell

Bioorg Med Chem Lett· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis